STOCK TITAN
  1. Home
  2. News
  3. BHC

Bausch Health Companies Inc. - BHC STOCK NEWS

Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global leader in the pharmaceutical, medical device, and over-the-counter product industries, primarily focusing on the therapeutic areas of eye health, gastroenterology, and dermatology. The company is dedicated to advancing global health through innovation and efficient healthcare solutions.

With approximately 22,000 employees worldwide, Bausch Health operates in around 100 countries. The company's core business is organized into five segments: Salix Pharmaceuticals, International, Solta Medical, Diversified Products, and Bausch + Lomb, with the Bausch + Lomb segment generating the highest revenue. Bausch Health consistently delivers on its commitments to quality health care outcomes and customer focus.

Recent achievements include significant progress in the development of Amiselimod, a promising new treatment for ulcerative colitis, and the expansion of public drug plan listings for UCERIS® (budesonide) aerosol foam in multiple Canadian provinces. Additionally, Bausch Health has launched an awareness campaign for XIFAXAN®, an FDA-approved medication for reducing the risk of overt hepatic encephalopathy recurrence.

Financially, Bausch Health reported strong performance in the first quarter of 2024, with revenues of $2.15 billion, marking a 11% increase compared to the prior year. The company continues to strengthen its balance sheet while advancing its R&D pipeline and executing commercial strategies for global growth.

Bausch Health remains focused on protecting its intellectual property, as evidenced by recent litigation efforts to defend the XIFAXAN® franchise. The company is also committed to fostering partnerships and collaborations to enhance its product offerings and reach.

For more information, visit www.bauschhealth.com.

News

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Rhea-AI Summary
Bausch Health Companies Inc. announces the availability of ARAZLO, a topical prescription treatment for acne vulgaris, through BC PharmaCare in Canada. ARAZLO is the only tazarotene lotion approved by Health Canada for acne treatment in patients 10 years and older. The lotion's PRISMATREX technology helps improve patient tolerability, making it a significant addition to Bausch Health's dermatology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
News

Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals

Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals, Inc. filed a lawsuit against Amneal Pharmaceuticals for seeking approval to market a generic version of XIFAXAN®. The litigation process under the Hatch-Waxman Act has been initiated, triggering a 30-month stay of potential FDA approval for Amneal's ANDA. Bausch Health remains confident in its XIFAXAN® intellectual property and continues to defend it.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.92%
Tags
none
-
News

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Rhea-AI Summary
Bausch Health, Canada Inc., a part of Bausch Health Companies Inc., announces the first public drug plan listings for UCERIS® aerosol foam to treat distal ulcerative colitis in adults. The treatment is now available in five Canadian provinces, with a focus on expanding access to effective therapies for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
none
News

Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations

Rhea-AI Summary
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc., released its fourth annual Patient Perspectives IBS Impact Report. The report, in partnership with Fairleigh Dickinson University Poll, surveyed over 850 U.S adults with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). Findings show that a significant portion of patients feel isolated and hide symptoms from loved ones, with many skipping events due to IBS symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
News

Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Rhea-AI Summary
Bausch Health Companies Inc. and Salix Pharmaceuticals support a Phase 2 study of RELISTOR in head and neck cancer patients. The study aims to assess the potential of MNTX in treating oral cavity squamous cell carcinoma, led by Dr. Juan P. Cata at MD Anderson Cancer Center. The trial involves preoperative and postoperative MNTX administration with monitoring for two years. Primary and secondary endpoints include drug administration success, tumor characteristics, response rates, and patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
clinical trial
-
News

New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure

Rhea-AI Summary
Bausch Health Companies Inc. (BHC) and Salix Pharmaceuticals release findings from a colonoscopy awareness survey, highlighting patient perspectives on the procedure and preparation process. The survey, conducted in partnership with The Harris Poll, sheds light on barriers to colonoscopy uptake among U.S. residents aged 45+.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
News

Bausch Health Companies to Present at Cowen Annual Health Care Conference

Rhea-AI Summary
Bausch Health Companies Inc. (BHC) to participate in Cowen Annual Health Care Conference on March 5, 2024. A fireside chat will be hosted by the management team at 12:50 p.m. EST. Investors can access the live webcast on the company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
conferences
-
News

Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results

Rhea-AI Summary
Bausch Health Companies Inc. reports fourth-quarter revenues of $2.41 billion, up 10%, and full-year revenues of $8.76 billion, up 8%. The company shows growth in Salix, International, Solta, and Bausch + Lomb segments. GAAP Net Loss is $39 million for the quarter and $592 million for the year. Adjusted EBITDA is $869 million for the quarter and $3.0 billion for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
earnings
-
News

Salix Announces 2024 Gastrointestinal Health Scholars Program

Rhea-AI Summary
Bausch Health Companies Inc. announces the 2024 Salix Gastrointestinal Health Scholars Program, offering scholarships of up to $10,000 to 10 students living with GI diseases. Application period closes on May 6, 2024, with recipients notified in the summer of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
News

Bausch Health Announces Board Refreshment

Rhea-AI Summary
Bausch Health Companies Inc. announced the nomination of two independent and diverse candidates to stand for election to its Board of Directors at the Company's 2024 Annual Meeting of Shareholders. Christian A. Garcia, Former Executive Vice President and CFO of BrandSafway Industries, LLC, and Frank D. Lee, CEO of Pacira Biosciences, Inc., are the nominees. In addition, Russel C. Robertson and Thomas W. Ross, Sr. will be retiring from the Board and will not stand for re-election at the Company's 2024 Annual Meeting. The Company expects Mr. Garcia to serve as the Audit and Risk Committee chair and Mr. Lee to serve on the Talent and Compensation Committee. The 2024 Annual Meeting has not yet been scheduled.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

The current stock price of Bausch Health Companies (BHC) is $8.48 as of November 15, 2024.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately 3.2B.

What are the primary areas of focus for Bausch Health?

Bausch Health specializes in eye health, gastroenterology, and dermatology.

How many employees does Bausch Health have?

Bausch Health employs approximately 22,000 people worldwide.

In how many countries does Bausch Health operate?

Bausch Health operates in around 100 countries.

What is Bausch Health's largest revenue-generating segment?

The Bausch + Lomb segment generates the highest revenue for Bausch Health.

What recent product development has Bausch Health achieved?

Bausch Health has made significant progress with Amiselimod, a new treatment for ulcerative colitis.

What financial performance did Bausch Health report for Q1 2024?

Bausch Health reported Q1 2024 revenues of $2.15 billion, an 11% increase from the previous year.

How is Bausch Health protecting its intellectual property?

Bausch Health is actively involved in litigation to defend its intellectual property, particularly for the XIFAXAN® franchise.

Where can I find more information about Bausch Health?

More information is available at www.bauschhealth.com.

What recent public drug plan listings has Bausch Health achieved in Canada?

UCERIS® aerosol foam has been listed in the public drug plans of several Canadian provinces, including Ontario, Quebec, and Alberta.

Who is the brand ambassador for the XIFAXAN® awareness campaign?

Award-winning actor Bellamy Young is the brand ambassador for the XIFAXAN® awareness campaign.

Stock BHC logo
Bausch Health Companies Inc.

NYSE:BHC

BHC Rankings

#1623 Ranked by Market Cap
N/A Ranked by Dividends

BHC Stock Data

3.17B
367.80M
11.08%
77.48%
3.27%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
QUEBEC